Cargando…

Correction: Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes in Treatment Intensification: A Retrospective Observational Single-Center Study

Detalles Bibliográficos
Autores principales:	Yamada, Hodaka, Yoshida, Masashi, Suzuki, Daisuke, Funazaki, Shunsuke, Nagashima, Shuichi, Masahiko, Kimura, Kiyoshi, Otsuka, Hara, Kazuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981821/ https://www.ncbi.nlm.nih.gov/pubmed/36627460 http://dx.doi.org/10.1007/s13300-022-01365-2

Ejemplares similares

Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes in Treatment Intensification: A Retrospective Observational Single-Center Study
por: Yamada, Hodaka, et al.
Publicado: (2022)

Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings
por: Yamada, Hodaka, et al.
Publicado: (2023)

Retrospective Study of IDegLira, a New Fixed-Ratio Combination, in Japanese Patients With Type 2 Diabetes Mellitus: Analysis of Background Factors Affecting Effectiveness After 6 Months of Treatment
por: Yamada, Hodaka, et al.
Publicado: (2023)

Sodium–glucose cotransporter 2 inhibitors improved time‐in‐range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective, single‐center, pilot study
por: Suzuki, Daisuke, et al.
Publicado: (2020)

A novel mechanism of imeglimin‐mediated insulin secretion via the cADPR‐TRP channel pathway
por: Funazaki, Shunsuke, et al.
Publicado: (2021)

Pseudo Intestinal Obstruction Caused by Malignant Paraganglioma
por: Funazaki, Shunsuke, et al.
Publicado: (2021)

Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index
por: Yabe, Daisuke, et al.
Publicado: (2022)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Risk Factors of Hypoglycemic Encephalopathy and Prolonged Hypoglycemia in Patients With Severe Hypoglycemia
por: Saikawa, Rika, et al.
Publicado: (2019)

Effect of Liraglutide on Type B Insulin Resistance Syndrome and Insulin Allergy in Type 2 Diabetes: A Case Report
por: Matsumoto, Yuko, et al.
Publicado: (2017)

Spontaneous pregnancy after full recovery from hypopituitarism caused by lymphocytic hypophysitis
por: Funazaki, Shunsuke, et al.
Publicado: (2018)

Association between Urinary Calcium Excretion and Estimated Glomerular Filtration Rate Decline in Patients with Type 2 Diabetes Mellitus: A Retrospective Single-center Observational Study
por: Yamada, Hodaka, et al.
Publicado: (2018)

Background Factors Determining the Introduction and Dosage of Insulin in Women With Gestational Diabetes Mellitus
por: Matsumoto, Yuko, et al.
Publicado: (2019)

Spontaneous recovery of immune checkpoint inhibitor‐induced thyroiditis with high free T4 level: A case report
por: Hagiwara, Rie, et al.
Publicado: (2021)

Diabetic ketoacidosis producing extreme hyperkalemia in a patient with type 1 diabetes on hemodialysis
por: Yamada, Hodaka, et al.
Publicado: (2017)

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
por: Johansen, Pierre, et al.
Publicado: (2019)

Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma
por: Yamada, Hodaka, et al.
Publicado: (2022)

The Urinary Phosphate to Serum Fibroblast Growth Factor 23 Ratio, Deemed the Nephron Index, Is a Useful Clinical Index for Early Stage Chronic Kidney Disease in Patients with Type 2 Diabetes: An Observational Pilot Study
por: Yamada, Hodaka, et al.
Publicado: (2018)

A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
por: Ikushima, Ippei, et al.
Publicado: (2018)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
por: Kaku, Kohei, et al.
Publicado: (2018)

Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
por: Carlsson Petri, Kristin Cecilie, et al.
Publicado: (2018)

Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
por: Hunt, Barnaby, et al.
Publicado: (2019)

Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?
por: Colin, Ides M, et al.
Publicado: (2022)

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
por: Menzen, Markus, et al.
Publicado: (2023)

A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes
por: Webb, Neil, et al.
Publicado: (2018)

The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
por: Vidal, Josep, et al.
Publicado: (2020)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Improved treatment satisfaction in patients with type 2 diabetes treated with once‐weekly semaglutide in the SUSTAIN trials
por: Jendle, Johan, et al.
Publicado: (2019)

Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
Publicado: (2020)

Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
por: Garcia de Lucas, Maria Dolores, et al.
Publicado: (2022)

Efficacy and safety of once‐weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post‐hoc analysis
por: Araki, Eiichi, et al.
Publicado: (2022)

Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
por: Malkin, Samuel J. P., et al.
Publicado: (2018)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials
por: Alabduljabbar, Khaled, et al.
Publicado: (2022)

Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
por: Sandhu, Hera, et al.
Publicado: (2023)

Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis
por: Nomoto, Hiroshi, et al.
Publicado: (2023)

Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis
por: Shi, Fang-Hong, et al.
Publicado: (2018)

Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
por: Blundell, John, et al.
Publicado: (2017)

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lqsjgdoqjufrdniiobb138657f